Nomura Securities Starts Valeant Pharmaceuticals (VRX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Valeant Pharmaceuticals (VRX) Subpoena 'Far from Certain', UBS Says; Sees Bounce Back in Stock
September 29, 2015 8:46 AM EDTUBS analyst Marc Goodman reiterated a Buy rating and $285 price target on Valeant Pharmaceuticals (NYSE: VRX) following yesterday's sell-off amid news Democratic members of the House Committee on Oversight and Govt Reform sent a letter requesting Chairman Jason Chaffetz (Republican) to subpoena Valeant to turn over documents related to price increases for these products.
Goodman notes that, importantly,... More
Fear and Uncertainty Creates Buying Opportunity in Valeant (VRX) - BMO Capital
September 29, 2015 7:50 AM EDTBMO Capital analyst Alex Arfaei has come out to defend Valeant Pharmaceuticals (NYSE: VRX) which has been under pressure amid the political backlash over soaring drug prices, including yesterday's request for a subpoena from all 18 Democratic... More
